New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds

Add time:07/18/2019    Source:sciencedirect.com

Pyruvate kinase M2 (PKM2) is a key protein responsible for cancer’s Warburg effect. Activation of PKM2 may alter aberrant metabolism in cancer cells, which suggests PKM2 as a tumor selective therapeutic target. In this paper, the lead compound 8 was first discovered as a new kind of PKM2 activator from a random screening of an in-house compound library. Then, a series of lead compound 8 analogs were designed, synthesized and evaluated for their activation of PKM2 and anticancer activities. 7-Azaindole analog 32 was identified as the most potent PKM2 activator. Compounds with potent enzyme activity also exhibited selective anti-proliferation activity on cancer cell lines HCT116, Hela and H1299 compared with non-tumor cell line BEAS-2B. The structure–activity relationships of these compounds were supported by molecular docking results. Preliminary pharmacological studies also showed that compound 32 arrests the cell cycle at the G2/M phase in HCT116 cell line.

We also recommend Trading Suppliers and Manufacturers of [3-(Dimethylamino)propyl]dithiocarbamic acid (cas 18997-72-3). Pls Click Website Link as below: cas 18997-72-3 suppliers

Prev:Synthesis of pyridines with an amino acid residue by [2+2] cycloadditions of electron-poor acetylenes on enaminone systems derived from N-Boc protected amino acids
Next:Stereochemical investigation in the 1,3-dipolar cycloadditions of 3-nitro-2-phenyl-2H-1-benzopyrans to diazoalkanes: Synthesis and antimicrobial activity of novel benzopyranopyrazole derivatives)